The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens
Abstract
BACKGROUND: Polymyxin B is a last-line therapy for multidrug-resistant gram-negative bacteria. There is a dearth of pharmacokinetic data to guide dosing in critically ill patients. METHODS: Twenty-four critically ill patients were enrolled and blood/urine samples were collected over a dosing interval at steady state. Polymyxin B concentrations were measured by liquid chromatography-tandem mass spectrometry. Population pharmacokinetic analysis and Monte Carlo simulations were conducted. RESULTS: Twenty-four patients aged 21-87 years received intravenous polymyxin B (0.45-3.38 mg/kg/day). Two patients were on continuous hemodialysis, and creatinine clearance in the other patients was 10-143 mL/min. Even with very diverse demographics, the total body clearance of polymyxin B when scaled by total body weight (population mean, 0.0276 L/hour/kg) showed remarkably low interindividual variability (32.4% coefficient of variation). Polymyxin B was predominantly nonrenally cleared with median urinary recovery of 4.04%. Polymyxin B total body clearance did not show any relationship with creatinine clearance (r(2) = 0.008), APACHE II score, or age. Median unbound fraction in plasma was 0.42. Monte Carlo simulations revealed the importance of initiating therapeutic regimens with a loading dose. CONCLUSIONS: Our study showed that doses of intravenous polymyxin B are best scaled by total body weight. Importantly, dosage selection of this drug should not be based on renal function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Self-citationQuantification of Lean Bodyweight
Janmahasatian, S., Duffull, S. B., Ash, S., Ward, L. C., Byrne, N. M., & Green, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00004 · Cited by 900
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Self-citationGaronzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Self-citationLandman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-08 · Cited by 565
Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., Karaiskos, I., Poulakou, G., Kontopidou, F., Armaganidis, A., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01361-08 · Cited by 494
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-06 · Cited by 366
Self-citationMohamed, A. F., Karaiskos, I., Plachouras, D., Karvanen, M., Pontikis, K., Jansson, B., Papadomichelakis, E., Antoniadou, A., Giamarellou, H., Armaganidis, A., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06426-11 · Cited by 234
Dudhani, R. V., Turnidge, J. D., Coulthard, K., Milne, R. W., Rayner, C. R., Li, J., & Nation, R. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01114-09 · Cited by 205
Self-citation
Cited by
Poirel, L., Jayol, A., & Nordmann, P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-16 · Cited by 1,447
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Lee, C.-R., Lee, J. H., Park, M., Park, K. S., Bae, I. K., Kim, Y. B., Cha, C.-J., Jeong, B. C., & Lee, S. H. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00055 · Cited by 1,016
Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Self-citation
Metadata
- Authors
- Sandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., Nation, R. L., Li, J., & Zavascki, A. P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-05-22
- Volume
- 57
- Issue
- 4
- Pages
- 524-531
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2170001997
- Cited by
- 430
- References
- 16
- FWCI
- 20.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens. https://app.cochat.ai/papers/10.1093/cid/cit334
- The paper
- Sandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., Nation, R. L., Li, J., & Zavascki, A. P. (2013). Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cit334
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.